All News

Article

Acute Inflammatory Responses Needed to Resolve Chronic Pain

Jack Cush, MD May 16, 2022

Science Translational Medicine has published results of a Canadian study of low back pain (LBP) suggests that pain control by anti-inflammatory treatments might have negative effects on pain duration and may be counterproductive for long-term pain outcomes.

Article

Bimekizumab Development Delayed by FDA

Jack Cush, MD May 16, 2022

UCB announced they have received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis (PSO).

24 week, Phase II RCT of baricitinib in 314 active #SLE patients showed significant reductions in levels of dsDNA, IgG, Sm & ACL Abs; but had no effect on C3/C4, RNP, SSA, SSB. Changes in dsDNA did not correlate with SRI-4 responses though.https://t.co/cF6rHbtvf9 https://t.co/zXnUImaLHF

https://bit.ly/3FSWXmF

FDA has approved baricitinib (Olumiant) for the Treatment of Certain Hospitalized Patients with COVID-19 who require supplemental O2, mechanical ventilation, ECMO. Rec dose: 4-mg once daily for 14 days or until hospital discharge https://t.co/RiEp01tc0v https://t.co/f3RvUAzdRp

https://bit.ly/3FQLuEm

Cool NEJM Case of Spinal Gout in 82-yr-old woman with 3-wk hx of severe LBP, rigors, anorexia, incomplete urination. Hx of PsA, CKD, CHF treated w/ Humira, HCQ, diuretics. Imaging tophi in spine, responded to steroids and allopurinol. https://t.co/JgH2bPsDeu https://t.co/RAPNxohe55

https://bit.ly/3lhksww

New podcast available on Methotrexate Monitoring. Download wherever you get your podcasts. Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow. https://t.co/TQiUMdS4R0 https://t.co/vgejiV3hUl

https://bit.ly/3yFH1CM

Study of 198 RMD pts, vaccinated 91% JAKi and 80% MTX mono pts were Ab+ for spike protein. Adjusting MTX or JAKi did not significantly alter the immunogenicity (S1 spike Abs). DMARD adjustments w/ COVID-19 VAX may not be needed. https://t.co/ebw172M5I4 https://t.co/vjXqTbuD5t

https://bit.ly/3yLosgN

ASCORE: Seropositivity Favors Abatacept Drug Survival The ASCORE study evaluated efficacy, safety, and drug retention (durability) of ABA in moderate-to-severe RA and found consistently better ABA durability in those who were seropositive. https://t.co/dLFC3dW4Tv https://t.co/LNCUIQjnGf

https://bit.ly/39m9Vxm

Can You Reduce Frequency of Methotrexate Monitoring? https://t.co/TnXZVCTv10 https://t.co/4q8sWwQ5aC

https://bit.ly/3M8PXEG

Wiki Guidelines Approach to Pyogenic Osteomyelitis https://t.co/PaYolXmPv3 https://t.co/AXrwhRjQs4

https://bit.ly/3MhrwVG

Polygenic Risk Scores to Identfy Severe Knee and Hip Osteoarthritis This study identified genetic risk variants from genome-wide association analysis of OA patients to calculate PRSs associated with subsequent need for joint replacement surgery. https://t.co/ZhAiuFu8iw https://t.co/OsR6p9m2S9

https://bit.ly/3LcY5D1

Lumbar spinal stenosis affects 103 million worldwide (11% of older adults in US). 1st line Rx is activity modification, analgesia, PT. Benefits of epidural steroids havent been established. Decompressive surgery only for selected pts w/ pain & limitation https://t.co/qdC8VXC1ko https://t.co/C67sB6IFVL

https://bit.ly/3PmojGo

NEJM has published results of 2 phase 3 trials (BRAVE-AA1, BRAVE-AA2) demonstrating the efficacy of Baricitinib in aduls with severe alopecia areata - BARI was superior to placebo in hair regrowth by week 36 https://t.co/I88bvuU4cg https://t.co/4xNH0IZnGA

https://bit.ly/3wb1opN

Small RCT 39 pts with #PMR given tocilizumab or placebo. Steroid-free remission at wk 16 was 64% on tocilizumab (63.2%) and 12% placebo. Mean time to first relapse was shorter with PBO (82 vs 130days). 5 SAE PBO, 1 TCZ https://t.co/FJjDxm7wfQ https://t.co/EiuSGaXgeh

https://bit.ly/38mGpYe

Acne with JAK Inhibitors JAK inhibitors have become enormously popular and while their side effect profile has been delineated and reviewed, little mention is made of acne – an adverse event that may affect up to one-quarter of patients taking JAKi. https://t.co/ADzaBjgsAN https://t.co/Yydo47UGYl

https://bit.ly/3N7gemM

Welcome to the latest update from #SLEEducatorsNetwork, with Dr. Askanase, Director of the Lupus Center @Columbia who explains why a deeper understanding of SLE pathophysiology may help us better address its underlying mechanisms. Sponsored by GSK USMA. https://t.co/LFfZAFgMWE https://t.co/n8X45pInYQ

https://bit.ly/3yuXY2S

Early results from the U-ENDURE, Phase 3 RCT of upadacitinib in adult Crohns disease. Pts responding to UPA 45 mg/d were given PBO or UPA (15 or 30 mg). 52 wk UPA achieved CDAI (37% & 48% vs 15% PBO)& endoscopic remission (28% & 40% vs 7%) https://t.co/eo2KtNOUW8 https://t.co/MKnTxVEkth

https://bit.ly/3w8E1xh

2019 Gabapentin Rx=69 million; 7th most common Rx in USA. MMWR: 62,652 overdose deaths, 52% had Pos. gabapentin test. OD deaths w/ GAB involved usually involved illicitly manufactured fentanyls. GAB+Opioids=BAD COMBO! https://t.co/qQbPmwzAgJ

https://bit.ly/3laKKjG

EADV Dermatology Meeting presents data on the 2 year safety of Deucravacitinib, (TYK2 inhibitor); also showing DEUC is effective in scalp, nail, & palmoplantar PSO. Data from the phase 3 POETYK PSO-1 and PSO-2 trials https://t.co/cFz6XkpA69 https://t.co/ZNJzph6i5N https://t.co/QJZEhzqkY4

https://bit.ly/3PegvWZ

Topics

All News

Acute Inflammatory Responses Needed to Resolve Chronic Pain

Bimekizumab Development Delayed by FDA

Do you get our email newsletter?